Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference

Jan 25, 2016, 07:00 ET from Biocept, Inc.

SAN DIEGO, Jan. 25, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session at the Personalized Medicine World Conference (PMWC) 2016.  The conference is being held in Mountain View, Calif.

"We are happy to participate in this important conference that brings together experts from diverse fields to discuss innovations aimed at advancing personalized medicine," said Mr. Nall.  "I am proud of Biocept's role in providing assays that use a simple blood draw to profile and monitor multiple types of cancers.  Our tests provide actionable information that can assist physicians with personalizing treatments for their patients with cancer in order to improve outcomes."  

About the Personalized Medicine World Conference

Personalized Medicine World Conference (PMWC), in its 10th year, is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. The conference showcases practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic.  PMWC 2016 is expected to bring together nearly 1,100 key opinion leaders and stakeholders in the personalized medicine field.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in plasma. Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer and melanoma, and plans to introduce additional CLIA-validated assays in the near term. For additional information, please visit www.biocept.com.

Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO

 

SOURCE Biocept, Inc.



RELATED LINKS

http://www.biocept.com